131
Participants
Start Date
May 31, 2007
Primary Completion Date
November 30, 2009
Study Completion Date
November 30, 2009
Docetaxel
Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.
Prednisone
Prednisone 5 mg orally twice daily.
Intetumumab
Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
Placebo
Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
Birmingham
Los Angeles
San Bernardino
Wichita
Shreveport
Charleston
North Charleston
Graz
Vienna
Wels
Antwerp
Brasschaat
Brussels
Haine-Saint-Paul, La Louviere
Leuven
Liÿge
Ottignies
Roeselare
Tournai
Wilrijk
Aschaffenburg
Berlin
Cologne
Freiburg im Breisgau
Kirchheim
Marburg
München
Tübingen
Ahmedabad
Bangalore
Chennai
Mumbai
New Delhi
Pune
Apeldoorn
Leiden
Maastricht
Nijmegen
The Hague
Bydgoszcz
Gdansk
Inowrocław
Kościerzyna
Lodz
Lublin
Moscow
Moscow Region
Saint Petersburg
St-Petersburg Leningrad
Voronezh
Yaroslavl
Yekaterinburg
Johannesburg Gauteng
Pretoria
Pretoria Gauteng
Cambridge
Leicester
Lincoln
London
Lead Sponsor
Centocor, Inc.
INDUSTRY